Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2007

View Archived Issues

Novel antiinflammatory agents disclosed in recent patent literature

Studies reveal potential of CS-917 in type 2 diabetes

Studies advance immunomodulating agents for diabetes

Phase II findings warrant advancement of ispinesib for breast cancer

New data on treatments for diabetic complications: neuropathy, gastroparesis

Proof of concept obtained for HMPL-004 in ulcerative colitis

Recent patents impart new therapeutic agents for respiratory disorders

FemmePharma initiates clinical trial for pain associated with breast disease

Bayer introduces more convenient formulation of Kogenate FS

4SC completes enrollment for a phase IIa trial for rheumatoid arthritis

Cylene Pharmaceuticals initiates phase II trial of Quarfloxin for cancer

New data indicate activity of perifosine in multiple myeloma

FDA approves clinical trials of ralfinamide for neuropathic pain

Wilex to file SPA for CA9-SCAN

Karo Bio delays development of KB-5359 for dyslipidemia

New agents for renal and urological disorders reported by Toray

Novel long-acting GLP-1 analogues presented at the ADA meeting

Novel adenosine A2B receptor antagonist improves insulin sensitivity in vivo

Newly identified frog-derived ribonuclease could be a future cancer therapy

Wyeth and Karo Bio extend atherosclerosis collaboration

Positive phase I/II results for ALKS-29 in alcohol-dependent patients

Phase I data indicate activity of Quadramet in multiple myeloma

Positive results of subcutaneous methylnaltrexone extension study

Santhera inlicenses omigapil for congenital muscular dystrophy

New data support role of Velcade in front-line multiple myeloma treatment

SIRT2: a new target in Parkinson's disease

Tamiflu approved in 30 mg and 45 mg doses

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...